New — Free Peptide Starter Guide (2026): 13 chapters, 34 cited studies

Get it free
ToolsCompareSomatropin (HGH) vs Cartalax

Somatropin (HGH) vs Cartalax

Side-by-side comparison of key properties, dosing, and research.

Growth Hormone PeptidesAnti-Aging & Longevity
Somatropin (HGH)
Anti-Aging & Longevity
Cartalax
Summary
Somatropin is recombinant human growth hormone (rhGH), identical in structure to the 191-amino acid pituitary-derived growth hormone. It is FDA-approved for growth hormone deficiency, short stature, and wasting conditions. Off-label, it is widely explored for body composition, anti-aging, and performance enhancement, though significant risks accompany unsupervised use.
Cartalax is a tetrapeptide bioregulator (Ala-Glu-Asp-Pro) developed by Professor Vladimir Khavinson for cartilage and connective tissue. It is tissue-specific for chondrocytes and cartilaginous structures, supporting cartilage matrix synthesis, slowing degenerative changes, and promoting joint longevity. It is used in the context of osteoarthritis, joint aging, and athletic cartilage preservation.
Half-Life
2-3 hours (subcutaneous); 20-30 minutes (intravenous)
Short (minutes); gene-regulatory effects are sustained
Admin Route
Subcutaneous, Intramuscular (less common)
SubQ, Oral
Research
Typical Dose
0.15-0.3 mg/day (adults); titrated to IGF-1 levels
10 mg per day
Frequency
Once daily
Daily for 10–30 days
Key Benefits
  • Increases lean muscle mass and reduces body fat (particularly visceral)
  • Restores growth hormone deficiency (FDA-approved)
  • Improves bone mineral density
  • Enhances exercise capacity and recovery
  • Supports skin thickness and collagen synthesis
  • Improves lipid profile in GHD patients
  • Explored for anti-aging and cellular regeneration
  • Supports cartilage matrix synthesis and maintenance
  • May slow progression of osteoarthritic cartilage degradation
  • Reduces chondrocyte apoptosis
  • Promotes joint longevity in aging and high-impact sports
  • Anti-aging effects on connective tissue
  • Complementary to BPC-157 and TB-500 in joint recovery protocols
  • Well tolerated in available human and animal research
Side Effects
  • Fluid retention and edema (common, dose-dependent)
  • Carpal tunnel syndrome
  • Joint and muscle pain
  • Insulin resistance and elevated blood glucose
  • +3 more
  • Generally well tolerated
  • Mild injection site reactions
  • No significant adverse events reported at standard doses
Stacks With